游离脂肪酸受体在肺部疾病中的研究进展  

Research progress of free fatty acid receptors in lung diseases

作　　者：陈敬华 李建妍 李琪[1] Chen Jinghua;Li Jianyan;Li Qi(Department of Respiratory Medicine,the First Affiliated Hospital of Hainan Medical College the Respiratory Medical Center of Hainan Province,Haikou 570102,China)

机构地区：[1]海南医学院第一附属医院呼吸内科海南省呼吸疾病中心,海口570102

出　　处：《国际呼吸杂志》2024年第2期235-240,共6页International Journal of Respiration

基　　金：国家自然科学基金(82160012、82260001);海南省重大科技专项(ZDKJ2021036);海南省创新团队项目(820CXTD448);海南省重点研发计划国际科技合作项目(GHYF2022011);海南省重点研发项目(ZDYF2020223)。

摘　　要：游离脂肪酸受体(FFAR)是一类具有多功能性的G蛋白偶联受体,参与细胞内信号传导,调节细胞凋亡、炎症反应、免疫反应和能量代谢等生物学过程。近年来,国内外多项研究发现,FFAR在肺部疾病中发挥着重要作用,有望成为防治呼吸系统疾病的潜在研究靶点。本文对FFAR在哮喘、肺部感染、急性肺损伤、慢性阻塞性肺疾病、特发性肺纤维化等疾病发展中的作用及机制作一综述,以期为呼吸系统疾病的防控、干预提供新的方向。Free fatty acid receptors(FFAR)are a class of multifunctional G protein-coupled receptors that are involved in intracellular signaling,regulating apoptosis,inflammatory response,immune response,energy metabolism,and other biological processes.In recent years,a large number of studies have found that FFAR play an important role in lung diseases.So FFAR are expected to become a potential target for preventing and treating respiratory diseases.This reviewaims to summarize the possible role of FFAR inasthma,lung infection,acute lung injury,chronic obstructive pulmonary disease(COPD),idiopathic pulmonary fibrosis,and other pulmonary diseases.It is expected to open up new avenues for the control and treatment of these respiratory diseases.

关 键 词：肺疾病 游离脂肪酸受体 G蛋白耦联受体 抗炎作用 

分 类 号：R563[医药卫生—呼吸系统]